X

Brooks Laboratories Ltd Stock Analysis

Small Cap
Evaluated by 493 users | BSE: 533543 | NSE: BROOKS |
Pharmaceuticals & Drugs
The Company was originally incorporated as Brooks Laboratories Limited on January 23, 2002. Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company set up a facility for manufacturing Tablets, Dry Syrup...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 29.91%16.5%7.27%6.69%7.03%9.3%1.76%-8.53%-9.32%-16.12%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 52.556.180.185.385.28057.555.75569.7
Y-o-Y Gr. Rt.-6.7%42.9%6.4%-0.1%-6.1%-28.1%-3.2%-1.2%26.6%
Adjusted EPS (Rs.) 5.874.553.683.733.95.460.86-7.12-7.76-9.48
Y-o-Y Gr. Rt.--22.5%-19.1%1.4%4.6%40%-84.3%-927.9%NANA
Book Value per Share (Rs.) 16.3945.3352.6156.1557.462.8766.0858.9751.3139.84
Adjusted Net Profit 78.87.17.27.610.61.7-13.8-15.1-23.4
Net Op. Cash Flow (Rs. Cr.) 4-0.85.410.72.18.19.6-6.2-5.1-9.4
Debt to Cash Flow from Ops 2.19-1.20.20.010.240.71.43-4.53-6.18-2.86
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Brooks Laboratories Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 3.2%-3.9%6.6%26.6%
Adjusted EPS -205.5%-219.4%-322.6%NA
Book Value per Share 10.4-7-15.5-22.4
Share Price 19.5% 0.2% -2.1% 206.4%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 42.1115.977.266.666.779.071.33-11.39-13.72-23.02
Operating Profit Margin (%) 17.6418.6613.11108.0513.948.76-16.02-15.19-3.69
Net Profit Margin (%) 13.2515.768.928.58.8913.242.9-24.8-27.37-33.62
Debt to Equity 0.450.010.01000.050.110.240.310.27
Working Capital Days 128156173193184216227208234206
Cash Conversion Cycle 18344335222527-77
Entity Percentage Holding
Promoters 66.41%
Non-Institutions 33.59%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Brooks Laboratories Ltd's performance infers:

Brooks Laboratories Ltd earnings have declined by -219.4%, whereas share price has appreciated 0.2% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

Data is not available for this company

The Company was originally incorporated as Brooks Laboratories Limited on January 23, 2002. Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development centre at Baddi, Himachal Pradesh. The Company started its commercial production in the month of June 2006 and became

The Company was originally incorporated as Brooks Laboratories Limited on January 23, 2002. Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development centre at Baddi, Himachal Pradesh. The Company started its commercial production in the month of June 2006 and became profitable from the very first year of its production.

The company has set up a well equipped manufacturing unit at Baddi, Himachal Pradesh in the year 2006 and has been awarded a G.M.P Certification for following Good Manufacturing Practices under “Revised Schedule M” of Drugs & Cosmetics Rules, 1945 in respect of various categories of Tablets, Capsules, Liquid Orals, Dry Syrups, SVP (Liquid & Dry) and Ophthalmic Section by The Health & Family Welfare Department, Himachal.

Company’s manufacturing facility at Baddi is capable of manufacturing products confirming to TRS 908 of 2003 (WHO GMP) standards. Its Quality Management System at the factory at Baddi is certified as complying to ISO 9001:2008.

Product of the company

The company has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials. These products are manufactured in accordance with highest international standards in facilities as per norms of WHO-GMP & ISO 9000-2008.

Some of the product categories are:

  • Beta Lactum
  • Cephalosporins
  • Carbapenems
  • General Injectable (Dry Powder)
  • General Injectable (Liquid)
  • Cortico Steroids
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback